Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

In vivo antiangiogenic activity of Immusol's new compound, IMS-2186

May 7, 2007

A novel SIRT1 activator from Sirtris shows neuroprotective effects in optic neuritis in vivo

May 7, 2007

Tbeta4 cleared for phase II study in diabetics undergoing vitrectomy surgery

May 4, 2007

FDA approves AzaSite for bacterial conjunctivitis

May 2, 2007

Novagali cleared to begin U.S. phase III study of Nova-22007

April 30, 2007

CHMP to recommend that occult indication be deleted from Visudyne E.U. label

April 27, 2007

Enrollment ongoing in phase III study of Medidur for DME

April 27, 2007

Two phase II/III trials evaluate NT-501 in retinitis pigmentosa

April 20, 2007

FDA grants orphan drug status to ganciclovir for acute herpetic keratitis

April 19, 2007

Sirion raises financing to advance pipeline

April 13, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.